Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002571 · ClinicalTrials.gov registry record · Phase 2
SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT00002571 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 52 participants.
The verdict
NCT00002571, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Antiviral therapy may be effective treatment for AIDS-related lymphoma. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, radiation therapy, and antiviral therapy in treating patients who have AIDS-related lymphoma.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
- DRUG cytarabine
- BIOLOGICAL bleomycin sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 1994-06 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002571
The ClinicalTrials.gov registry entry for NCT00002571 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002571 about?
NCT00002571 is a clinical study titled "SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Antiviral therapy may be effective treatment for AIDS-related lymphoma. PURPOSE: Phase II trial to study the eff...
What is the current status of trial NCT00002571?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 1994-06. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00002571?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), cytarabine (DRUG), bleomycin sulfate (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002571?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.